Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

aTYR PHARMA (ATYR) Return on Sales (2019 - 2025)

aTYR PHARMA's Return on Sales history spans 7 years, with the latest figure at 408.56% for Q4 2025.

  • For Q4 2025, Return on Sales fell 11957.0% year-over-year to 408.56%; the TTM value through Dec 2025 reached 408.56%, down 11957.0%, while the annual FY2025 figure was 408.56%, 11957.0% down from the prior year.
  • Return on Sales reached 408.56% in Q4 2025 per ATYR's latest filing, down from 140.76% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.77% in Q4 2022 to a low of 408.56% in Q4 2025.
  • Average Return on Sales over 5 years is 110.33%, with a median of 53.26% recorded in 2023.
  • Peak YoY movement for Return on Sales: crashed -25385bps in 2024, then skyrocketed 14882bps in 2025.
  • A 5-year view of Return on Sales shows it stood at 14.77% in 2021, then surged by 95bps to 0.77% in 2022, then plummeted by -20225bps to 155.58% in 2023, then tumbled by -86bps to 289.0% in 2024, then crashed by -41bps to 408.56% in 2025.
  • Per Business Quant, the three most recent readings for ATYR's Return on Sales are 408.56% (Q4 2025), 140.76% (Q3 2025), and 289.0% (Q4 2024).